The trials, the rulings and the studies that actually affect you, summarised for a busy woman and linked to the original source. No hype. No diet talk. Just what changed and what it means for you.
New NIQ and IGD data shows 12% of UK households now include a GLP-1 user, and 80% say it changed how the whole home eats. Protein and fibre went up. Everything else went down.
A BMJ study of tens of thousands of adults links GLP-1 use to more recorded hair loss. The named mechanism is rapid weight loss and nutrient shortfalls, not the drug.
Philly Pretzel Factory, Campbell's and Honeygrow are rebuilding products around protein and fibre as GLP-1 use spreads. What the new labels are actually worth.
Bloomberg Law found hundreds of foods and supplements sold as "GLP-1 friendly". There is no federal definition of the phrase, and the FDA says it has no action planned.
A scoping review of 129 GLP-1 trials found only 10 reported dietary outcomes. Eating guidance on a GLP-1 comes from nutrition science, not from the drug labels.
A June 2026 meta-analysis of 28 trials puts tirzepatide vs semaglutide head to head. Tirzepatide won on weight, but the best drug is the one you stay on.
A new analysis of the large SURMOUNT trial found tirzepatide produced about the same weight loss, roughly 20%, whether a woman was premenopausal, perimenopausal or postmenopausal. A separate study suggests hormone therapy may add to the effect.
Semaglutide cut knee osteoarthritis pain substantially in the STEP-9 trial, and 2026 lab work hints at direct cartilage protection. What it means for women on a GLP-1.
A study of 60,000 patients found that about 40% stopped their GLP-1 within a year, but most started again soon after: 42% within a year, nearly 60% within two. The weight tends to come back, and so do they.
The FDA has proposed formally barring pharmacies from making compounded copies of semaglutide, tirzepatide and liraglutide. It is the end of the cheaper, copied versions that filled the shortage years.
New research links GLP-1 use to a modest rise in osteoporosis: roughly 4% of users versus 3% of non-users. The likely cause is not the drug itself but the rapid weight and muscle loss that comes with it, which is preventable.
In the first randomised human trial to look at it, semaglutide slowed several markers of biological ageing by around 9%. The likely reason: less inflammation and less fat around the organs.
AstraZeneca's once-daily pill, elecoglipron, helped people with type 2 diabetes lose about 10.5% of their body weight in six months, with no injection required. The results were published in The Lancet.
More than 12,000 doctors and researchers met in New Orleans for the American Diabetes Association's 2026 sessions. The theme this year was a quiet shift: these drugs are no longer judged only by the scale.
A combination of semaglutide and an experimental drug called bimagrumab reached 22% weight loss with almost all of it coming from fat: lean mass loss was held to under 3%, versus 7.4% on semaglutide alone.
Novo Nordisk's CagriSema, which combines semaglutide with a second appetite hormone, delivered about 14% weight loss in its REIMAGINE trials. Good numbers, but analysts felt they looked modest next to the competition.
Boehringer Ingelheim's survodutide, a two-hormone drug, produced up to 16.6% weight loss over 76 weeks in its first large Phase 3 trial, adding yet another serious option to a fast-filling field.
In 26,000 adults who had both obesity and an autoimmune disease, GLP-1 users had a 44% lower risk of death, plus fewer heart events, ER visits and blood clots. Autoimmune conditions fall mostly on women.
Pfizer's experimental injection kept working when patients switched from weekly to monthly dosing, with up to 12.3% weight loss at 28 weeks. A once-a-month GLP-1 may genuinely be on the way.
A WashU and VA study mapping 175 outcomes across 2 million people links GLP-1 brain benefits to lower dementia, addiction and self-harm risk.
A study of more than 110,000 women presented at the ASCO cancer meeting found GLP-1 users were up to 47% less likely to develop breast cancer. Intriguingly, the weight loss alone did not appear to account for all of it.
A Rice University study found GLP-1 stigma and judgment runs deeper than expected: medication users were judged more harshly than dieters, or non-losers.
An investigational 1-hour endoscopic 'gut reset' (DMR) blunted weight regain after stopping Ozempic-class drugs in the REMAIN-1 trial. Promising, early, still investigational.
We read the journals and the trial readouts so you don't have to, then send one calm summary on Sunday mornings. Unsubscribe in one click.
